[
  {
    "objectID": "thesis.html",
    "href": "thesis.html",
    "title": "NeuroScope",
    "section": "",
    "text": "The Role of Inflammation in Alzheimer’s Development\nINTRODUCTION\nAlzheimer’s disease (AD) is a progressive neurodegenerative disorder that leads to memory loss, confusion, and a gradual decline in both cognitive and physical abilities (Alzheimer's Association, 2023). As global life expectancy continues to rise, the prevalence of AD is also increasing, which places a lot pressure on patients, their families, and healthcare systems around the world (Prince et al., 2015). Today, AD ranks among the leading causes of dementia and disability in older adults, which causes serious challenges not only to patients but also to caregivers and society as a whole (World Health Organization, 2022).\nFor decades, the predominant explanation for Alzheimer’s has been the “amyloid hypothesis,” which credits the disease to the accumulation of amyloid-beta plaques and tau tangles in the brain (Hardy & Selkoe, 2002). These abnormal protein build-ups disrupt neuronal communication, trigger cell death, and have been central to most research and therapeutic strategies (Selkoe & Hardy, 2016). Genetic factors, such as the APOE4 gene, have also been linked to increased risk and progression of AD (Liu et al., 2013). While the amyloid hypothesis has guided much of the scientific investigation, treatments targeting amyloid plaques have mostly fallen short in giving significant clinical benefits (Cummings et al., 2019). This has led researchers to explore alternative mechanisms that may contribute to the onset and progression of Alzheimer’s.\nEmerging evidence points to chronic inflammation as a critical driver of AD pathology. Unlike acute inflammation, which is a short-term and protective immune response, chronic inflammation is a prolonged state that disrupts normal physiological functions (Heppner et al., 2015). In the brain, this persistent inflammation can arise from factors such as metabolic dysfunction, oxidative stress, and unhealthy lifestyle habits (Heneka et al., 2015). Over time, these triggers activate immune cells like microglia and astrocytes, which, instead of protecting neurons, begin to release inflammatory molecules that damage healthy brain cells (Glass et al., 2010). This inflammatory environment not only accelerates the formation of amyloid plaques and tau tangles but also impairs synaptic communication and neuronal survival (Wyss-Coray & Rogers, 2012).\nThis paper argues that chronic inflammation is not merely a byproduct of Alzheimer’s disease but a fundamental contributor to its development and progression. Specifically, this paper proposes that metabolic and immune dysregulation underlie the chronic inflammatory state observed in AD. Understanding how inflammation interacts with other pathological processes, such as amyloid and tau aggregation, may provide crucial insights into the disease’s mechanisms. By targeting the root causes of neuroinflammation—whether through lifestyle interventions, anti-inflammatory treatments, or metabolic regulation—we may open new avenues for slowing or even preventing the progression of Alzheimer’s disease (Heneka et al., 2018).\nThis hypothesis is supported by recent studies that link inflammation markers to cognitive decline (Walker et al., 2019) and displays the presence of pro-inflammatory cytokines in the brains of Alzheimer’s patients (Suarez-Calvet et al., 2016). Additionally, experimental models have shown that reducing inflammation can better neuronal damage and improve cognitive function (Yin et al., 2021). These findings highlight the need to shift our focus beyond amyloid-centric approaches and towards addressing the multifaceted role of inflammation in AD. By doing so, we can move closer to developing more effective therapeutic strategies for this devastating disease.\nTHE ROLE OF NEUROINFLAMMATION IN ALZHEIMER’S PATHOLOGY\nNeuroinflammation is now recognized as a major contributor to Alzheimer’s disease. A key part of this is the role of microglia which are immune cells in the brain that keep things balanced by responding to injuries, infections, and other disruptions. In Alzheimer’s disease, microglia (the brain’s resident immune cells) are constantly activated. This is different from their normal transient activation during acute immune responses (Heneka et al., 2015). This chronic activation causes a cascade of damaging effects, including the release of pro-inflammatory cytokines like IL-1β and TNF-α, as well as reactive oxygen species, which lead to synaptic dysfunction and neuronal death (Glass et al., 2010; Suarez-Calvet et al., 2016). As microglia continuously attack neurons, they contribute to the disruption of synaptic connections and increase cognitive decline and memory impairments characteristic of Alzheimer’s disease (Wyss-Coray & Rogers, 2012). This suggests that microglial dysregulation is a central mechanism driving neurodegeneration in AD, perpetuating the cycle of inflammation and neuronal loss. This highlights how immune dysregulation contributes not just to neuronal loss but also to the overall progression of AD.\nAs stated above, cytokines have a prominent role in Alzheimer's disease. Key molecules like interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) all have higher levels in the brains of people with AD. As a result, synaptic function and plasticity are affected. The increase in cytokine levels not only helps trigger the hyperphosphorylation of tau (a major hallmark of AD) which weakens neurons even more (Wyss-Coray & Rogers, 2012), they also make it easier for amyloid plaques to form. This creates a cycle of inflammation and neuronal damage.\nIn addition to the direct effects of cytokines, a key part of AD is the back-and-forth between amyloid-beta build-up and brain inflammation. When amyloid-beta plaques pile up in the brains of people with Alzheimer’s, they signal to fire inflammatory molecules from microglia, which then speed up the deposits of even more amyloid-beta. This cycle of plaques causing inflammation, and inflammation causing more plaques, really drives the progression of the disease. Studies suggest that breaking this loop could help lower plaque build-up and slow down the disease, making neuroinflammation an exciting target for new treatments (Heppner et al., 2015). Since the link between amyloid-beta and inflammation is very complicated, targeting the inflammation might help stop this. Ths gives hope for future therapies that could delay or even prevent Alzheimer’s. Thus, getting a better handle on inflammation is essential for finding more effective treatments.\nGENETIC RISK FACTORS AND INFLAMMATORY PATHWAYS\nGenetic factors play a crucial role in determining the risk of developing Alzheimer’s disease (AD), with differences in certain genes significantly influencing the brain's inflammatory responses. Among these, changes in the TREM2 gene and the APOE4 allele are particularly noteworthy for their contributions to the onset and progression of Alzheimer's disease. These genetic factors are linked not only to an increased susceptibility to AD but also to the modulation of neuroinflammation, a hallmark of the disease.\nOne of the most studied genes in relation to Alzheimer's risk is TREM2 (Triggering Receptor Expressed on Myeloid Cells 2). TREM2 is involved in the functioning of microglia. Variations in the TREM2 gene, particularly rare mutations, have been shown to impair the ability of microglia to respond effectively to neurodegenerative signals. As a result, this increases neuroinflammation and accelerates the progression of AD. Guerreiro et al. (2013) demonstrated that mutations in the TREM2 gene lead to a big reduction in the ability of microglia to efficiently manage amyloid-beta plaques and other neurotoxic agents. This impairment not only results in the accumulation of amyloid plaques but also contributes to a chronic inflammatory environment that exacerbates neuronal damage. The disruption of microglial clearance and the subsequent rise in inflammatory cytokines fuels the neurodegenerative process, creating a cycle that accelerates cognitive decline.\nIn addition to TREM2 mutations, the APOE4 allele is another major genetic risk factor for Alzheimer's disease. APOE4, a variant of the apolipoprotein E gene, has been well established as a genetic variant that increases the risk of Alzheimer’s and is particularly associated with an earlier onset of the disease. The presence of the APOE4 allele has been shown to enhance inflammation in the brain by promoting the production of pro-inflammatory molecules, including cytokines and chemokines. According to Mahley and Huang (2012), APOE4 not only increases the production of these inflammatory molecules but also impairs the ability of microglia to clear amyloid-beta plaques, leading to a further accumulation of plaques and greater neuronal damage. In particular, APOE4 has been shown to alter the response of microglia, making them less effective at resolving inflammation and promoting tissue repair, thus worsening the neurodegenerative process (Li et al., 2015).\nTogether, these genetic factors highlight the central role of immune dysfunction in the pathogenesis of Alzheimer's disease. Both TREM2 mutations and the APOE4 allele emphasize how genetic variations can influence the brain’s inflammatory pathways and contribute to the disease. The findings suggest that addressing neuroinflammation, potentially through the influence of microglial activity or the inhibition of pro-inflammatory signaling pathways, could be a promising therapeutic strategy for Alzheimer’s disease. These insights have opened new avenues for research aimed at understanding the intricate relationship between genetics, inflammation, and neurodegeneration in Alzheimer's. Further studies on the interaction between genetic risk factors and inflammatory processes are essential for developing targeted interventions that may help mitigate the devastating effects of Alzheimer’s disease.\nPERIPHERAL INFLAMMATION AND ITS CONTRIBUTION TO ALZHEIMER’S\nPeripheral inflammation plays a large complex role in kickstarting and speeding the progression of Alzheimer’s disease. It’s driven by several factors that ramp up body-wide inflammation and set off inflammatory responses in the brain. One major player in this process is the gut-brain axis, which Cryan and colleagues (2019) explored. They showed that gut bacteria have a real impact on brain inflammation. Emerging evidence suggests that gut microbiota imbalances, or dysbiosis, contribute to systemic inflammation, which can exacerbate neuroinflammation in Alzheimer’s disease. Dysbiosis has been shown to elevate inflammatory markers such as C-reactive protein (CRP) and pro-inflammatory cytokines in the bloodstream (Cryan et al., 2020). These markers may cross the blood-brain barrier, triggering inflammatory responses in the central nervous system (Fung et al., 2017). In the context of AD, such inflammation promotes the aggregation of amyloid-beta plaques and tau tangles, accelerating disease progression (Cattaneo et al., 2017; Harach et al., 2017). These findings underscore the potential role of the gut-brain axis in modulating neuroinflammation and highlight the need for therapeutic strategies targeting gut health to mitigate AD progression. Cryan et al. also point out a connection between metabolic problems, like obesity, insulin resistance, and brain inflammation. They propose that inflammation triggered by these metabolic problems might contribute to AD. Of these, insulin resistance plays a big role in Alzheimer’s development since it can harm brain function and encourage the buildup of amyloid plaques.\nCraft (2005) highlights how systemic diseases, especially heart problems and diabetes, contribute to brain inflammation and cognitive decline. Conditions like high blood pressure, high cholesterol, and type 2 diabetes raise the chances of developing Alzheimer's by increasing peripheral inflammation throughout the body. These diseases boost the levels of pro-inflammatory cytokines, which can make their way to the brain and activate glial cells. This kind of chronic inflammation is a major risk factor for cognitive decline and brain cell damage, and having these conditions over time speeds up the development of Alzheimer's.\nBesides metabolic and cardiovascular factors, chronic stress also plays a big role in inflammation and its link to Alzheimer's disease. According to McEwen (2012), stress hormones, especially cortisol, can harm the brain by triggering the production of inflammatory molecules. Long-term exposure to high cortisol levels has been linked to a higher risk of cognitive decline and dementia, as it also activates microglia. On top of that, stress-related inflammation can make other Alzheimer’s risk factors, like high blood pressure worse, creating a cycle that speeds up cognitive decline. McEwen’s research shows how our social environment, particularly chronic stress, can play a key role in the development of AD.\nCONTRASTING PERSPECTIVES: IS INFLAMMATION A CAUSE OR EFFECT?\nThe understanding of inflammation's role in Alzheimer’s disease (AD) has evolved significantly, with two primary perspectives emerging. Historically, the amyloid cascade hypothesis, introduced by Hardy and Higgins (1992), has dominated the field. This hypothesis posits that amyloid-beta plaques are the central cause of AD, with inflammation acting as a secondary response to plaque accumulation. According to this view, the presence of plaques causes a series of detrimental processes, including the activation of microglia and other immune cells (Heneka et al., 2015; Glass et al., 2010). In this framework, inflammation is regarded as an unavoidable consequence of amyloid accumulation, amplifying the damage and presenting a secondary target for therapeutic intervention (Wyss-Coray & Rogers, 2012).\nHowever, this traditional view has been challenged. Herrup (2015) argues against the primacy of amyloid-beta as the primary driver of AD and questions whether inflammation is merely a downstream effect. He proposes that AD may instead originate from natural cellular dysfunction, such as damaged repair mechanisms or the failure of vital cellular processes. For example, defects in DNA repair or mitochondrial function can compromise neuronal health, leading to cellular stress and subsequent inflammation (Cai et al., 2012; Swerdlow, 2018). According to Herrup, these fundamental cellular problems may precede or occur independently of amyloid-beta accumulation and inflammation. From this outlook, amyloid-beta buildup is seen as a consequence rather than a cause of cellular dysfunction, and inflammation may arise as a reaction to cellular stress rather than playing a causative role in disease progression.\nThis shift in focus away from amyloid-beta as the primary culprit suggests that treatments exclusively targeting amyloid plaques may not address the underlying causes of AD. For instance, clinical trials of amyloid-targeting therapies have shown limited success in improving cognition, further supporting the need to explore alternative mechanisms (Cummings et al., 2019). Herrups hypothesis calls for a broader investigation into the cellular dysfunctions that precede or occur alongside amyloid-beta accumulation and inflammation. Such an approach highlights the need to explore any relationships between these factors. Demonstrating that inflammation is not merely an effect, but a contributing cause of AD remains a significant challenge in the current state of research. Nonetheless, longitudinal studies and experimental models are beginning to provide evidence that chronic inflammation can directly influence amyloid-beta production and tau pathology, offering new insights into disease progression (Heppner et al., 2015; Heneka et al., 2018).\nThese differing perspectives underscore the complexity of Alzheimer’s disease. They emphasize the importance of continued research to unravel how inflammation, amyloid-beta, and cellular dysfunction interact in the progression of the disease. Understanding these relationships will be critical in developing comprehensive approaches to prevent and treat AD effectively. By focusing on the interplay between inflammation and cellular health, researchers may uncover novel therapeutic strategies that address the root causes of Alzheimer’s disease, potentially slowing or halting its progression.\nCONCLUSION\nIn conclusion, neuroinflammation is increasingly recognized as a critical factor in Alzheimer’s disease (AD), prompting a shift in focus from the traditional viewpoint on amyloid plaques and tau tangles. Studies have demonstrated that inflammation in the brain is not merely a consequence of AD but a driving force that increases neuronal and synaptic damage. This ultimately contributes to cognitive decline and memory loss (Heneka et al., 2015; Heppner et al., 2015). Activation of glial cells, particularly microglia and astrocytes, leads to the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), while also disrupting the blood-brain barrier. Altogether, hese processes accelerate the progression of AD by amplifying neurodegeneration and facilitating the accumulation of amyloid-beta and tau pathology (Wyss-Coray & Rogers, 2012; Sweeney et al., 2019).\nGiven this evidence, neuroinflammation has emerged as a promising target for therapeutic interventions. Recent research has identified specific inflammatory pathways, such as the NLRP3 inflammasome and complement system, as potential areas for therapeutic focus (Heneka et al., 2018; Hong et al., 2016). Moving forward, it is important to dive deeper into the complex interactions between inflammation and other pathological processes in AD, including oxidative stress, mitochondrial dysfunction, and vascular abnormalities (Swerdlow, 2018; Cai et al., 2012). This integrative understanding could pave the way for novel treatments that address the root causes of AD by modulating inflammatory responses.\nBy recognizing inflammation as a key player rather than a secondary effect, researchers and clinicians can develop more comprehensive strategies for diagnosing, preventing, and treating AD. These strategies may include anti-inflammatory therapies, lifestyle changes, and interventions targeting the gut-brain axis to reduce systemic inflammation (Cummings et al., 2019; Cryan et al., 2020). These advances have the potential to transform the way we look at Alzheimer’s disease, offering hope for improved outcomes, quality of life, and perhaps even prevention in the future. Ultimately, this shift highlights the importance of addressing inflammation as part of an alternative approach to combating AD.\nWorks Cited\n\nAlzheimer’s Disease Facts and Figures. (n.d.). In Alzheimer’s Disease and Dementia. Alzheimer’s Disease and Dementia. Retrieved December 14, 2024, from https://www.alz.org/alzheimers-dementia/facts-figures\nCattaneo, A., Cattane, N., & Galluzzi, S. (n.d.). Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. National Library of Medicine. Retrieved December 14, 2024, from https://pubmed.ncbi.nlm.nih.gov/27776263\nCraft, S. (2005). Insulin resistance syndrome and Alzheimer’s disease: age- and obesity-related effects on memory, amyloid, and inflammation. In Neurobiology of aging: Vol. 26 Suppl 1 (pp. 65–69). Neurobiology of aging. https://doi.org/10.1016/j.neurobiolaging.2005.08.021\nCummings, J. L., Tong, G., & Ballard, C. (2019). Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options. In Journal of Alzheimer’s disease: JAD (Vol. 67, Issue 3, pp. 779–794). Journal of Alzheimer’s disease: JAD. https://doi.org/10.3233/JAD-180766\nFung, T. C., Olson, C. A., & Hsiao, E. Y. (2017). Interactions between the microbiota, immune and nervous systems in health and disease. National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/28092661\nHarach, T., Marungruang, N., Duthilleul, N., Cheatham, V., McCoy, K. D., Frisoni, G., Neher, J. J., Fk, F., Jucker, M., Lasser, T., & Bolmont, T. (2017). Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. In Scientific reports (Vol. 7, pp. 41802–41802). Scientific reports. https://doi.org/10.1038/srep41802\nHardy, J. A., & Higgins, G. A. (1992). Alzheimer’s disease: the amyloid cascade hypothesis. National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/1566067\nHeneka, M. T., McManus, R. M., & Latz, E. (2018). Inflammasome signalling in brain function and neurodegenerative disease. In Nature reviews. Neuroscience (Vol. 19, Issue 10, pp. 610–621). Nature reviews. Neuroscience. https://doi.org/10.1038/s41583-018-0055-7\nHerrup, K. (2015). The case for rejecting the amyloid cascade hypothesis. In Nature neuroscience (Vol. 18, Issue 6, pp. 794–799). Nature neuroscience. https://doi.org/10.1038/nn.4017\nHong, S. (2016). Complement and microglia mediate early synapse loss in Alzheimer mouse models. National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/27033548\nMcEwen, B. S. (1993). Brain on stress: how the social environment gets under the skin. National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/23045648\nSweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019). Blood-Brain Barrier: From Physiology to Disease and Back. In Physiological reviews (Vol. 99, Issue 1, pp. 21–78). Physiological reviews. https://doi.org/10.1152/physrev.00050.2017\nSwerdlow, R. H. (n.d.). Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease. National Library of Medicine. Retrieved December 14, 2024, from https://pubmed.ncbi.nlm.nih.gov/29036828\nZhang, G., Wang, Z., Hu, H., Zhao, M., & Sun, L. (2021). Microglia in Alzheimer’s Disease: A Target for Therapeutic Intervention. In Frontiers in cellular neuroscience (Vol. 15, pp. 749587–749587). Frontiers in cellular neuroscience. https://doi.org/10.3389/fncel.2021.749587\nGlass, C. K. (2010). Mechanisms underlying inflammation in neurodegeneration. National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/20303880\nHardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/12130773\nHeneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., Herrup, K., Frautschy, S. A., Finsen, B., Brown, G. C., Verkhratsky, A., Yamanaka, K., Koistinaho, J., Latz, E., Halle, A., … Golenbock, D. T. (2015). Neuroinflammation in Alzheimer’s disease. In The Lancet. Neurology (Vol. 14, Issue 4, pp. 388–405). The Lancet. Neurology. https://doi.org/10.1016/S1474-4422(15)70016-5\nHeppner, F. L., Ransohoff, R. M., & Becher, B. (2015). Immune attack: the role of inflammation in Alzheimer disease. In Nature reviews. Neuroscience (Vol. 16, Issue 6, pp. 358–372). Nature reviews. Neuroscience. https://doi.org/10.1038/nrn3880\nLi, X., Song, D., & Leng, S. X. (2015). Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment. In Clinical interventions in aging (Vol. 10, pp. 549–560). Clinical interventions in aging. https://doi.org/10.2147/CIA.S74042\nLiu, C.-C. (2013). Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/23296339\nMahley, R. W., & Huang, Y. (2012). Apolipoprotein E sets the stage: response to injury triggers neuropathology. In Neuron (Vol. 76, Issue 5, pp. 871–885). Neuron. https://doi.org/10.1016/j.neuron.2012.11.020\nSelkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer’s disease at 25 years. National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/27025652\nSuárez-Calvet, M., Kleinberger, G., Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., Sánchez-Valle, R., Antonell, A., Rami, L., Molinuevo, J. L., Brosseron, F., Trachsel, A., Heneka, M. T., Struyfs, H., Engelborghs, S., … Haass, C. (2016). sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer’s disease and associate with neuronal injury markers. In EMBO molecular medicine (Vol. 8, Issue 5, pp. 466–476). EMBO molecular medicine. https://doi.org/10.15252/emmm.201506123\nWyss-Coray, T., & Rogers, J. (n.d.). Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. National Library of Medicine. Retrieved December 14, 2024, from https://pubmed.ncbi.nlm.nih.gov/22315714\nCryan, J. F., O’Riordan, K. J., Sandhu, K., Peterson, V., & Dinan, T. G. (2020). The gut microbiome in neurological disorders. In The Lancet. Neurology (Vol. 19, Issue 2, pp. 179–194). The Lancet. Neurology. https://doi.org/10.1016/S1474-4422(19)30356-4\n\nGuerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., Hazrati, L., Collinge, J., Pocock, J., Lashley, T., Williams, J., Lambert, J.-C., Amouyel, P., Goate, A., Rademakers, R., … undefined Alzheimer Genetic Analysis Group. (2013). TREM2 variants in Alzheimer’s disease. In The New England journal of medicine (Vol. 368, Issue 2, pp. 117–127). The New England journal of medicine. https://doi.org/10.1056/NEJMoa1211851"
  },
  {
    "objectID": "posts/neuroinflammation-part-3/index.html#genetic-risk-factors-and-inflammatory-pathways",
    "href": "posts/neuroinflammation-part-3/index.html#genetic-risk-factors-and-inflammatory-pathways",
    "title": "Genetic Risk Factors and Inlammatory Pathways - Part III",
    "section": "GENETIC RISK FACTORS AND INFLAMMATORY PATHWAYS",
    "text": "GENETIC RISK FACTORS AND INFLAMMATORY PATHWAYS\nGenetic factors play a crucial role in determining the risk of developing Alzheimer’s disease (AD), with differences in certain genes significantly influencing the brain’s inflammatory responses. Among these, changes in the TREM2 gene and the APOE4 allele are particularly noteworthy for their contributions to the onset and progression of Alzheimer’s disease. These genetic factors are linked not only to an increased susceptibility to AD but also to the modulation of neuroinflammation, a hallmark of the disease.\nOne of the most studied genes in relation to Alzheimer’s risk is TREM2 (Triggering Receptor Expressed on Myeloid Cells 2). TREM2 is involved in the functioning of microglia. Variations in the TREM2 gene, particularly rare mutations, have been shown to impair the ability of microglia to respond effectively to neurodegenerative signals. As a result, this increases neuroinflammation and accelerates the progression of AD.(Guerreiro et al. 2013) demonstrated that mutations in the TREM2 gene lead to a big reduction in the ability of microglia to efficiently manage amyloid-beta plaques and other neurotoxic agents. This impairment not only results in the accumulation of amyloid plaques but also contributes to a chronic inflammatory environment that exacerbates neuronal damage. The disruption of microglial clearance and the subsequent rise in inflammatory cytokines fuels the neurodegenerative process, creating a cycle that accelerates cognitive decline.\nIn addition to TREM2 mutations, the APOE4 allele is another major genetic risk factor for Alzheimer’s disease. APOE4, a variant of the apolipoprotein E gene, has been well established as a genetic variant that increases the risk of Alzheimer’s and is particularly associated with an earlier onset of the disease. The presence of the APOE4 allele has been shown to enhance inflammation in the brain by promoting the production of pro-inflammatory molecules, including cytokines and chemokines. According to (Mahley and Huang 2012), APOE4 not only increases the production of these inflammatory molecules but also impairs the ability of microglia to clear amyloid-beta plaques, leading to a further accumulation of plaques and greater neuronal damage. In particular, APOE4 has been shown to alter the response of microglia, making them less effective at resolving inflammation and promoting tissue repair, thus worsening the neurodegenerative process (Li, Song, and Leng 2015).\n\nTogether, these genetic factors highlight the central role of immune dysfunction in the pathogenesis of Alzheimer’s disease. Both TREM2 mutations and the APOE4 allele emphasize how genetic variations can influence the brain’s inflammatory pathways and contribute to the disease. The findings suggest that addressing neuroinflammation, potentially through the influence of microglial activity or the inhibition of pro-inflammatory signaling pathways, could be a promising therapeutic strategy for Alzheimer’s disease. These insights have opened new avenues for research aimed at understanding the intricate relationship between genetics, inflammation, and neurodegeneration in Alzheimer’s. Further studies on the interaction between genetic risk factors and inflammatory processes are essential for developing targeted interventions that may help mitigate the devastating effects of Alzheimer’s disease.\n\nReferences\n\n\nGuerreiro, Rita, Aleksandra M. Wojtas, Jose T. Bras, Minerva M. Carrasquillo, Ekaterina Rogaeva, Elisa Majounie, Carlos Cruchaga, et al. 2013. “TREM2 Variants in Alzheimer’s Disease.” The New England Journal of Medicine 368 2: 117–27. https://api.semanticscholar.org/CorpusID:13902817.\n\n\nLi, Xiaohua, Dalin Song, and Sean Xiao Leng. 2015. “Link Between Type 2 Diabetes and Alzheimer’s Disease: From Epidemiology to Mechanism and Treatment.” Clinical Interventions in Aging 10: 549–60. https://api.semanticscholar.org/CorpusID:17366475.\n\n\nMahley, Robert W., and Yadong Huang. 2012. “Apolipoprotein e Sets the Stage: Response to Injury Triggers Neuropathology.” Neuron 76: 871–85. https://api.semanticscholar.org/CorpusID:6367826."
  },
  {
    "objectID": "posts/neuroinflammation-part-4/index.html#peripheral-inflammation-and-its-contribution-to-alzheimers",
    "href": "posts/neuroinflammation-part-4/index.html#peripheral-inflammation-and-its-contribution-to-alzheimers",
    "title": "Peripheral Inflammation and Alzheimer’s - Part IV",
    "section": "PERIPHERAL INFLAMMATION AND ITS CONTRIBUTION TO ALZHEIMER’S",
    "text": "PERIPHERAL INFLAMMATION AND ITS CONTRIBUTION TO ALZHEIMER’S\nPeripheral inflammation plays a large complex role in kickstarting and speeding the progression of Alzheimer’s disease. It’s driven by several factors that ramp up body-wide inflammation and set off inflammatory responses in the brain. One major player in this process is the gut-brain axis, which Cryan and colleagues explored. They showed that gut bacteria have a real impact on brain inflammation. Emerging evidence suggests that gut microbiota imbalances, or dysbiosis, contribute to systemic inflammation, which can exacerbate neuroinflammation in Alzheimer’s disease. Dysbiosis has been shown to elevate inflammatory markers such as C-reactive protein (CRP) and pro-inflammatory cytokines in the bloodstream (Cryan et al. 2019). These markers may cross the blood-brain barrier, triggering inflammatory responses in the central nervous system (Fung, Olson, and Hsiao 2017). In the context of AD, such inflammation promotes the aggregation of amyloid-beta plaques and tau tangles, accelerating disease progression [Cattaneo et al. (2017)](Harach et al. 2017). These findings underscore the potential role of the gut-brain axis in modulating neuroinflammation and highlight the need for therapeutic strategies targeting gut health to mitigate AD progression. Cryan et al. also point out a connection between metabolic problems, like obesity, insulin resistance, and brain inflammation. They propose that inflammation triggered by these metabolic problems might contribute to AD. Of these, insulin resistance plays a big role in Alzheimer’s development since it can harm brain function and encourage the buildup of amyloid plaques.\n(Craft 2005) highlights how systemic diseases, especially heart problems and diabetes, contribute to brain inflammation and cognitive decline. Conditions like high blood pressure, high cholesterol, and type 2 diabetes raise the chances of developing Alzheimer’s by increasing peripheral inflammation throughout the body. These diseases boost the levels of pro-inflammatory cytokines, which can make their way to the brain and activate glial cells. This kind of chronic inflammation is a major risk factor for cognitive decline and brain cell damage, and having these conditions over time speeds up the development of Alzheimer’s.\nBesides metabolic and cardiovascular factors, chronic stress also plays a big role in inflammation and its link to Alzheimer’s disease. According to (McEwen 2012), stress hormones, especially cortisol, can harm the brain by triggering the production of inflammatory molecules. Long-term exposure to high cortisol levels has been linked to a higher risk of cognitive decline and dementia, as it also activates microglia. On top of that, stress-related inflammation can make other Alzheimer’s risk factors, like high blood pressure worse, creating a cycle that speeds up cognitive decline. McEwen’s research shows how our social environment, particularly chronic stress, can play a key role in the development of AD.\n\n\nReferences\n\n\nCattaneo, Annamaria, Nadia Cattane, Samantha Galluzzi, Stefania Provasi, Nicola Lopizzo, Cristina Festari, Clarissa Ferrari, et al. 2017. “Association of Brain Amyloidosis with Pro-Inflammatory Gut Bacterial Taxa and Peripheral Inflammation Markers in Cognitively Impaired Elderly.” Neurobiology of Aging 49: 60–68. https://api.semanticscholar.org/CorpusID:207163214.\n\n\nCraft, Suzanne. 2005. “Insulin Resistance Syndrome and Alzheimer’s Disease: Age- and Obesity-Related Effects on Memory, Amyloid, and Inflammation.” Neurobiology of Aging 26: 65–69. https://api.semanticscholar.org/CorpusID:31262556.\n\n\nCryan, John F., Kenneth J. O’Riordan, Kiran V. Sandhu, Veronica L. Peterson, and Timothy G. Dinan. 2019. “The Gut Microbiome in Neurological Disorders.” The Lancet Neurology 19: 179–94. https://api.semanticscholar.org/CorpusID:208155450.\n\n\nFung, Thomas C., Christine A. Olson, and Elaine Y. Hsiao. 2017. “Interactions Between the Microbiota, Immune and Nervous Systems in Health and Disease.” Nature Neuroscience 20: 145–55. https://api.semanticscholar.org/CorpusID:4099782.\n\n\nHarach, Taoufiq, Nittaya Marungruang, N. Duthilleul, V. Cheatham, K. D. Mc Coy, Giovanni Battista Frisoni, Jonas J. Neher, et al. 2017. “Reduction of Abeta Amyloid Pathology in APPPS1 Transgenic Mice in the Absence of Gut Microbiota.” Scientific Reports 7. https://api.semanticscholar.org/CorpusID:3006742.\n\n\nMcEwen, Bruce S. 2012. “Brain on Stress: How the Social Environment Gets Under the Skin.” Proceedings of the National Academy of Sciences 109: 17180–85. https://api.semanticscholar.org/CorpusID:1106515."
  },
  {
    "objectID": "posts/neuroinflammation-part-1/index.html#introduction",
    "href": "posts/neuroinflammation-part-1/index.html#introduction",
    "title": "The Role of Inflammation in Alzheimer’s Development - Introduction",
    "section": "INTRODUCTION",
    "text": "INTRODUCTION\nAlzheimer’s disease (AD) is a progressive neurodegenerative disorder that leads to memory loss, confusion, and a gradual decline in both cognitive and physical abilities (Alzheimer’s Association, 2023). As global life expectancy continues to rise, the prevalence of AD is also increasing, which places a lot pressure on patients, their families, and healthcare systems around the world (Prince et al. 2015). Today, AD ranks among the leading causes of dementia and disability in older adults, which causes serious challenges not only to patients but also to caregivers and society as a whole (World Health Organization, 2022).\nFor decades, the predominant explanation for Alzheimer’s has been the “amyloid hypothesis,” which credits the disease to the accumulation of amyloid-beta plaques and tau tangles in the brain (Hardy and Selkoe 2009). These abnormal protein build-ups disrupt neuronal communication, trigger cell death, and have been central to most research and therapeutic strategies (Selkoe & Hardy, 2016).\n\nGenetic factors, such as the APOE4 gene, have also been linked to increased risk and progression of AD (Liu et al. 2013). While the amyloid hypothesis has guided much of the scientific investigation, treatments targeting amyloid plaques have mostly fallen short in giving significant clinical benefits (Cummings, Tong, and Ballard 2019). This has led researchers to explore alternative mechanisms that may contribute to the onset and progression of Alzheimer’s.\nEmerging evidence points to chronic inflammation as a critical driver of AD pathology. Unlike acute inflammation, which is a short-term and protective immune response, chronic inflammation is a prolonged state that disrupts normal physiological function (Heppner, Ransohoff, and Becher 2015).\n\nIn the brain, this persistent inflammation can arise from factors such as metabolic dysfunction, oxidative stress, and unhealthy lifestyle habits (Heneka et al. 2015). Over time, these triggers activate immune cells like microglia and astrocytes, which, instead of protecting neurons, begin to release inflammatory molecules that damage healthy brain cells (Glass et al. 2010). This inflammatory environment not only accelerates the formation of amyloid plaques and tau tangles but also impairs synaptic communication and neuronal survival (Wyss-Coray and Rogers 2012).\nThis paper argues that chronic inflammation is not merely a byproduct of Alzheimer’s disease but a fundamental contributor to its development and progression. Specifically, this paper proposes that metabolic and immune dysregulation underlie the chronic inflammatory state observed in AD. Understanding how inflammation interacts with other pathological processes, such as amyloid and tau aggregation, may provide crucial insights into the disease’s mechanisms. By targeting the root causes of neuroinflammation—whether through lifestyle interventions, anti-inflammatory treatments, or metabolic regulation—we may open new avenues for slowing or even preventing the progression of Alzheimer’s disease (Heneka, McManus, and Latz 2018).\nThis hypothesis is supported by recent studies that link inflammation markers to cognitive decline (Walker et al., 2019) and displays the presence of pro-inflammatory cytokines in the brains of Alzheimer’s patients (Suárez-Calvet et al. 2016). Additionally, experimental models have shown that reducing inflammation can better neuronal damage and improve cognitive function (Yin et al., 2021). These findings highlight the need to shift our focus beyond amyloid-centric approaches and towards addressing the multifaceted role of inflammation in AD. By doing so, we can move closer to developing more effective therapeutic strategies for this devastating disease.\n\nReferences\n\n\nCummings, Jeffrey L., Gary Tong, and Clive G Ballard. 2019. “Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options.” Journal of Alzheimer’s Disease 67: 779–94. https://api.semanticscholar.org/CorpusID:59339279.\n\n\nGlass, Christopher K., Kaoru Saijo, Beate Winner, Maria Carolina Marchetto, and Fred H. Gage. 2010. “Mechanisms Underlying Inflammation in Neurodegeneration.” Cell 140: 918–34. https://api.semanticscholar.org/CorpusID:4930569.\n\n\nHardy, John, and Dennis J. Selkoe. 2009. “The Amyloid Hypothesis of Alzheimer’s Disease : Progress and Problems on the Road to Therapeutics.” In. https://api.semanticscholar.org/CorpusID:15150253.\n\n\nHeneka, Michael T., Monica J. Carson, Joseph B. El Khoury, Gary E. Landreth, Frederic Brosseron, Douglas L. Feinstein, Andreas H. Jacobs, et al. 2015. “Neuroinflammation in Alzheimer’s Disease.” The Lancet Neurology 14: 388–405. https://api.semanticscholar.org/CorpusID:4705464.\n\n\nHeneka, Michael T., Róisín M. McManus, and Eicke Latz. 2018. “Inflammasome Signalling in Brain Function and Neurodegenerative Disease.” Nature Reviews Neuroscience 19: 610–21. https://api.semanticscholar.org/CorpusID:52188641.\n\n\nHeppner, Frank L., Richard M. Ransohoff, and Burkhard Becher. 2015. “Immune Attack: The Role of Inflammation in Alzheimer Disease.” Nature Reviews Neuroscience 16: 358–72. https://api.semanticscholar.org/CorpusID:6116253.\n\n\nLiu, Chia-Chen, Takahisa Kanekiyo, Huaxi Xu, and Guojun Bu. 2013. “Apolipoprotein e and Alzheimer Disease: Risk, Mechanisms and Therapy.” Nature Reviews Neurology 9: 184–84. https://api.semanticscholar.org/CorpusID:46045450.\n\n\nPrince, Martin James, Anders Wimo, Maëlenn Guerchet, Gemma-Claire Ali, Yu-Tzu Wu, and Matthew A. Prina. 2015. “World Alzheimer Report 2015 - the Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends.” In. https://api.semanticscholar.org/CorpusID:6408388.\n\n\nSuárez-Calvet, Marc, Gernot Kleinberger, Miguel Ángel Araque Caballero, Matthias Brendel, Axel Rominger, Daniel Alcolea, Juan Fortea, et al. 2016. “sTREM2 Cerebrospinal Fluid Levels Are a Potential Biomarker for Microglia Activity in Early‐stage Alzheimer’s Disease and Associate with Neuronal Injury Markers.” EMBO Molecular Medicine 8: 466–76. https://api.semanticscholar.org/CorpusID:970691.\n\n\nWyss-Coray, Tony, and Joseph Rogers. 2012. “Inflammation in Alzheimer Disease-a Brief Review of the Basic Science and Clinical Literature.” Cold Spring Harbor Perspectives in Medicine 2 1: a006346. https://api.semanticscholar.org/CorpusID:13204499."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "My Blog",
    "section": "",
    "text": "The Role of Inflammation in Alzheimer’s Development - Conclusion\n\n\n\n\n\n\nThesis\n\n\n\n\n\n\n\n\n\nFeb 27, 2025\n\n\nNicholas Monogioudis\n\n\n\n\n\n\n\n\n\n\n\n\nInflammation: Cause or Effect? - Part V\n\n\n\n\n\n\nThesis\n\n\n\n\n\n\n\n\n\nFeb 23, 2025\n\n\nNicholas Monogioudis\n\n\n\n\n\n\n\n\n\n\n\n\nPeripheral Inflammation and Alzheimer’s - Part IV\n\n\n\n\n\n\nThesis\n\n\n\n\n\n\n\n\n\nFeb 21, 2025\n\n\nNicholas Monogioudis\n\n\n\n\n\n\n\n\n\n\n\n\nGenetic Risk Factors and Inlammatory Pathways - Part III\n\n\n\n\n\n\nThesis\n\n\n\n\n\n\n\n\n\nFeb 14, 2025\n\n\nNicholas Monogioudis\n\n\n\n\n\n\n\n\n\n\n\n\nNeuroinflammation in Alzheimer’s Pathology - Part II\n\n\n\n\n\n\nThesis\n\n\n\n\n\n\n\n\n\nFeb 10, 2025\n\n\nNicholas Monogioudis\n\n\n\n\n\n\n\n\n\n\n\n\nThe Role of Inflammation in Alzheimer’s Development - Introduction\n\n\n\n\n\n\nThesis\n\n\n\n\n\n\n\n\n\nFeb 6, 2025\n\n\nNicholas Monogioudis\n\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "posts/neuroinflammation-part-6/index.html#conclusion",
    "href": "posts/neuroinflammation-part-6/index.html#conclusion",
    "title": "The Role of Inflammation in Alzheimer’s Development - Conclusion",
    "section": "CONCLUSION",
    "text": "CONCLUSION\nIn conclusion, neuroinflammation is increasingly recognized as a critical factor in Alzheimer’s disease (AD), prompting a shift in focus from the traditional viewpoint on amyloid plaques and tau tangles. Studies have demonstrated that inflammation in the brain is not merely a consequence of AD but a driving force that increases neuronal and synaptic damage. This ultimately contributes to cognitive decline and memory loss [Heneka et al. (2015)](Heppner, Ransohoff, and Becher 2015). Activation of glial cells, particularly microglia and astrocytes, leads to the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), while also disrupting the blood-brain barrier. Altogether, these processes accelerate the progression of AD by amplifying neurodegeneration and facilitating the accumulation of amyloid-beta and tau pathology [Wyss-Coray and Rogers (2012)](Sweeney et al. 2019).\nGiven this evidence, neuroinflammation has emerged as a promising target for therapeutic interventions. Recent research has identified specific inflammatory pathways, such as the NLRP3 inflammasome and complement system, as potential areas for therapeutic focus [Heneka, McManus, and Latz (2018)](Hong et al. 2016). Moving forward, it is important to dive deeper into the complex interactions between inflammation and other pathological processes in AD, including oxidative stress, mitochondrial dysfunction, and vascular abnormalities [Swerdlow (2017)](Cai, Davis, and Sheng 2011). This integrative understanding could pave the way for novel treatments that address the root causes of AD by modulating inflammatory responses.\n\nBy recognizing inflammation as a key player rather than a secondary effect, researchers and clinicians can develop more comprehensive strategies for diagnosing, preventing, and treating AD. These strategies may include anti-inflammatory therapies, lifestyle changes, and interventions targeting the gut-brain axis to reduce systemic inflammation [Cummings, Tong, and Ballard (2019)](Cryan et al. 2019). These advances have the potential to transform the way we look at Alzheimer’s disease, offering hope for improved outcomes, quality of life, and perhaps even prevention in the future. Ultimately, this shift highlights the importance of addressing inflammation as part of an alternative approach to combating AD.\n\n\nReferences\n\n\nCai, Qian, Matthew L. Davis, and Zu-Hang Sheng. 2011. “Regulation of Axonal Mitochondrial Transport and Its Impact on Synaptic Transmission.” Neuroscience Research 70: 9–15. https://api.semanticscholar.org/CorpusID:22295837.\n\n\nCryan, John F., Kenneth J. O’Riordan, Kiran V. Sandhu, Veronica L. Peterson, and Timothy G. Dinan. 2019. “The Gut Microbiome in Neurological Disorders.” The Lancet Neurology 19: 179–94. https://api.semanticscholar.org/CorpusID:208155450.\n\n\nCummings, Jeffrey L., Gary Tong, and Clive G Ballard. 2019. “Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options.” Journal of Alzheimer’s Disease 67: 779–94. https://api.semanticscholar.org/CorpusID:59339279.\n\n\nHeneka, Michael T., Monica J. Carson, Joseph B. El Khoury, Gary E. Landreth, Frederic Brosseron, Douglas L. Feinstein, Andreas H. Jacobs, et al. 2015. “Neuroinflammation in Alzheimer’s Disease.” The Lancet Neurology 14: 388–405. https://api.semanticscholar.org/CorpusID:4705464.\n\n\nHeneka, Michael T., Róisín M. McManus, and Eicke Latz. 2018. “Inflammasome Signalling in Brain Function and Neurodegenerative Disease.” Nature Reviews Neuroscience 19: 610–21. https://api.semanticscholar.org/CorpusID:52188641.\n\n\nHeppner, Frank L., Richard M. Ransohoff, and Burkhard Becher. 2015. “Immune Attack: The Role of Inflammation in Alzheimer Disease.” Nature Reviews Neuroscience 16: 358–72. https://api.semanticscholar.org/CorpusID:6116253.\n\n\nHong, Soyon, Victoria F. Beja-Glasser, Bianca M. Nfonoyim, Arnaud Frouin, Shaoming Li, Saranya Ramakrishnan, Katherine M. Merry, et al. 2016. “Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models.” Science 352: 712–16. https://api.semanticscholar.org/CorpusID:206645135.\n\n\nSweeney, Melanie D., Zhen Zhao, Axel Montagne, Amy R. Nelson, and Berislav V. Zlokovic. 2019. “Blood-Brain Barrier: From Physiology to Disease and Back.” Physiological Reviews 99 1: 21–78. https://api.semanticscholar.org/CorpusID:52910512.\n\n\nSwerdlow, Russell H. 2017. “Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease.” Journal of Alzheimer’s Disease 62: 1403–16. https://api.semanticscholar.org/CorpusID:4394932.\n\n\nWyss-Coray, Tony, and Joseph Rogers. 2012. “Inflammation in Alzheimer Disease-a Brief Review of the Basic Science and Clinical Literature.” Cold Spring Harbor Perspectives in Medicine 2 1: a006346. https://api.semanticscholar.org/CorpusID:13204499."
  },
  {
    "objectID": "posts/neuroinflammation-part-5/index.html#contrasting-perspectives-is-inflammation-a-cause-or-effect",
    "href": "posts/neuroinflammation-part-5/index.html#contrasting-perspectives-is-inflammation-a-cause-or-effect",
    "title": "Inflammation: Cause or Effect? - Part V",
    "section": "CONTRASTING PERSPECTIVES: IS INFLAMMATION A CAUSE OR EFFECT?",
    "text": "CONTRASTING PERSPECTIVES: IS INFLAMMATION A CAUSE OR EFFECT?\nThe understanding of inflammation’s role in Alzheimer’s disease (AD) has evolved significantly, with two primary perspectives emerging. Historically, the amyloid cascade hypothesis, introduced by (Hardy and Higgins 1992), has dominated the field. This hypothesis posits that amyloid-beta plaques are the central cause of AD, with inflammation acting as a secondary response to plaque accumulation. According to this view, the presence of plaques causes a series of detrimental processes, including the activation of microglia and other immune cells [Heneka et al. (2015)](Glass et al. 2010). In this framework, inflammation is regarded as an unavoidable consequence of amyloid accumulation, amplifying the damage and presenting a secondary target for therapeutic intervention (Wyss-Coray and Rogers 2012).\n\nHowever, this traditional view has been challenged. (Herrup 2015) argues against the primacy of amyloid-beta as the primary driver of AD and questions whether inflammation is merely a downstream effect. He proposes that AD may instead originate from natural cellular dysfunction, such as damaged repair mechanisms or the failure of vital cellular processes. For example, defects in DNA repair or mitochondrial function can compromise neuronal health, leading to cellular stress and subsequent inflammation [Cai, Davis, and Sheng (2011)](Swerdlow 2017). According to Herrup, these fundamental cellular problems may precede or occur independently of amyloid-beta accumulation and inflammation. From this outlook, amyloid-beta buildup is seen as a consequence rather than a cause of cellular dysfunction, and inflammation may arise as a reaction to cellular stress rather than playing a causative role in disease progression.\n\nThis shift in focus away from amyloid-beta as the primary culprit suggests that treatments exclusively targeting amyloid plaques may not address the underlying causes of AD. For instance, clinical trials of amyloid-targeting therapies have shown limited success in improving cognition, further supporting the need to explore alternative mechanisms (Cummings et al., 2019). Herrups hypothesis calls for a broader investigation into the cellular dysfunctions that precede or occur alongside amyloid-beta accumulation and inflammation. Such an approach highlights the need to explore any relationships between these factors. Demonstrating that inflammation is not merely an effect, but a contributing cause of AD remains a significant challenge in the current state of research. Nonetheless, longitudinal studies and experimental models are beginning to provide evidence that chronic inflammation can directly influence amyloid-beta production and tau pathology, offering new insights into disease progression [Heppner, Ransohoff, and Becher (2015)](Heneka, McManus, and Latz 2018).\nThese differing perspectives underscore the complexity of Alzheimer’s disease. They emphasize the importance of continued research to unravel how inflammation, amyloid-beta, and cellular dysfunction interact in the progression of the disease. Understanding these relationships will be critical in developing comprehensive approaches to prevent and treat AD effectively. By focusing on the interplay between inflammation and cellular health, researchers may uncover novel therapeutic strategies that address the root causes of Alzheimer’s disease, potentially slowing or halting its progression.\n\nReferences\n\n\nCai, Qian, Matthew L. Davis, and Zu-Hang Sheng. 2011. “Regulation of Axonal Mitochondrial Transport and Its Impact on Synaptic Transmission.” Neuroscience Research 70: 9–15. https://api.semanticscholar.org/CorpusID:22295837.\n\n\nGlass, Christopher K., Kaoru Saijo, Beate Winner, Maria Carolina Marchetto, and Fred H. Gage. 2010. “Mechanisms Underlying Inflammation in Neurodegeneration.” Cell 140: 918–34. https://api.semanticscholar.org/CorpusID:4930569.\n\n\nHardy, John, and Gerald A. Higgins. 1992. “Alzheimer’s Disease: The Amyloid Cascade Hypothesis.” Science 256 5054: 184–85. https://api.semanticscholar.org/CorpusID:35891486.\n\n\nHeneka, Michael T., Monica J. Carson, Joseph B. El Khoury, Gary E. Landreth, Frederic Brosseron, Douglas L. Feinstein, Andreas H. Jacobs, et al. 2015. “Neuroinflammation in Alzheimer’s Disease.” The Lancet Neurology 14: 388–405. https://api.semanticscholar.org/CorpusID:4705464.\n\n\nHeneka, Michael T., Róisín M. McManus, and Eicke Latz. 2018. “Inflammasome Signalling in Brain Function and Neurodegenerative Disease.” Nature Reviews Neuroscience 19: 610–21. https://api.semanticscholar.org/CorpusID:52188641.\n\n\nHeppner, Frank L., Richard M. Ransohoff, and Burkhard Becher. 2015. “Immune Attack: The Role of Inflammation in Alzheimer Disease.” Nature Reviews Neuroscience 16: 358–72. https://api.semanticscholar.org/CorpusID:6116253.\n\n\nHerrup, Karl. 2015. “The Case for Rejecting the Amyloid Cascade Hypothesis.” Nature Neuroscience 18: 794–99. https://api.semanticscholar.org/CorpusID:5500036.\n\n\nSwerdlow, Russell H. 2017. “Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease.” Journal of Alzheimer’s Disease 62: 1403–16. https://api.semanticscholar.org/CorpusID:4394932.\n\n\nWyss-Coray, Tony, and Joseph Rogers. 2012. “Inflammation in Alzheimer Disease-a Brief Review of the Basic Science and Clinical Literature.” Cold Spring Harbor Perspectives in Medicine 2 1: a006346. https://api.semanticscholar.org/CorpusID:13204499."
  },
  {
    "objectID": "posts/neuroinflammation-part-2/index.html#the-role-of-neuroinflammation-in-alzheimers-pathology",
    "href": "posts/neuroinflammation-part-2/index.html#the-role-of-neuroinflammation-in-alzheimers-pathology",
    "title": "Neuroinflammation in Alzheimer’s Pathology - Part II",
    "section": "THE ROLE OF NEUROINFLAMMATION IN ALZHEIMER’S PATHOLOGY",
    "text": "THE ROLE OF NEUROINFLAMMATION IN ALZHEIMER’S PATHOLOGY\nNeuroinflammation is now recognized as a major contributor to Alzheimer’s disease. A key part of this is the role of microglia which are immune cells in the brain that keep things balanced by responding to injuries, infections, and other disruptions. In Alzheimer’s disease, microglia (the brain’s resident immune cells) are constantly activated. This is different from their normal transient activation during acute immune responses (Heneka et al., 2015). This chronic activation causes a cascade of damaging effects, including the release of pro-inflammatory cytokines like IL-1β and TNF-α, as well as reactive oxygen species, which lead to synaptic dysfunction and neuronal death [Glass et al. (2010)](Suárez-Calvet et al. 2016). As microglia continuously attack neurons, they contribute to the disruption of synaptic connections and increase cognitive decline and memory impairments characteristic of Alzheimer’s disease (Wyss-Coray and Rogers 2012). This suggests that microglial dysregulation is a central mechanism driving neurodegeneration in AD, perpetuating the cycle of inflammation and neuronal loss. This highlights how immune dysregulation contributes not just to neuronal loss but also to the overall progression of AD.\n\nAs stated above, cytokines have a prominent role in Alzheimer’s disease. Key molecules like interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) all have higher levels in the brains of people with AD. As a result, synaptic function and plasticity are affected. The increase in cytokine levels not only helps trigger the hyperphosphorylation of tau (a major hallmark of AD) which weakens neurons even more (Wyss-Coray and Rogers 2012), they also make it easier for amyloid plaques to form. This creates a cycle of inflammation and neuronal damage.\nIn addition to the direct effects of cytokines, a key part of AD is the back-and-forth between amyloid-beta build-up and brain inflammation. When amyloid-beta plaques pile up in the brains of people with Alzheimer’s, they signal to fire inflammatory molecules from microglia, which then speed up the deposits of even more amyloid-beta. This cycle of plaques causing inflammation, and inflammation causing more plaques, really drives the progression of the disease. Studies suggest that breaking this loop could help lower plaque build-up and slow down the disease, making neuroinflammation an exciting target for new treatments (Heppner, Ransohoff, and Becher 2015). Since the link between amyloid-beta and inflammation is very complicated, targeting the inflammation might help stop this. Ths gives hope for future therapies that could delay or even prevent Alzheimer’s. Thus, getting a better handle on inflammation is essential for finding more effective treatments.\n\nReferences\n\n\nGlass, Christopher K., Kaoru Saijo, Beate Winner, Maria Carolina Marchetto, and Fred H. Gage. 2010. “Mechanisms Underlying Inflammation in Neurodegeneration.” Cell 140: 918–34. https://api.semanticscholar.org/CorpusID:4930569.\n\n\nHeppner, Frank L., Richard M. Ransohoff, and Burkhard Becher. 2015. “Immune Attack: The Role of Inflammation in Alzheimer Disease.” Nature Reviews Neuroscience 16: 358–72. https://api.semanticscholar.org/CorpusID:6116253.\n\n\nSuárez-Calvet, Marc, Gernot Kleinberger, Miguel Ángel Araque Caballero, Matthias Brendel, Axel Rominger, Daniel Alcolea, Juan Fortea, et al. 2016. “sTREM2 Cerebrospinal Fluid Levels Are a Potential Biomarker for Microglia Activity in Early‐stage Alzheimer’s Disease and Associate with Neuronal Injury Markers.” EMBO Molecular Medicine 8: 466–76. https://api.semanticscholar.org/CorpusID:970691.\n\n\nWyss-Coray, Tony, and Joseph Rogers. 2012. “Inflammation in Alzheimer Disease-a Brief Review of the Basic Science and Clinical Literature.” Cold Spring Harbor Perspectives in Medicine 2 1: a006346. https://api.semanticscholar.org/CorpusID:13204499."
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About Me",
    "section": "",
    "text": "Hello, my name is Nicholas Monogioudis, a recent neuroscience graduate passionate about clinical research, biotech, and AI in neuroscience.\n\n\nThis blog is where I share my insights on neuroscience, research breakthroughs, and industry trends, with a special focus on cognitive neuroscience, neuropharmacology, and neurotechnology.\nI aim to bridge the gap between complex neuroscience concepts and real-world applications, making cutting-edge research more accessible. Whether you’re a student, researcher, or simply someone curious about the brain, you’ll find content here on:\nThe latest discoveries in neuroscience and what they mean for the future\nDeep dives into cognitive processes, brain function, and neural networks\nHow neuroscience is shaping the pharmaceutical and biotech industries\nThe intersection of neuroscience with AI, brain-computer interfaces, and neurotech\nPersonal reflections on my journey in neuroscience and industry insights\n\n\n\nEducation: B.Sc. in Neuroscience from Temple University\nResearch Experience:\nResearch Assistant, Concepts and Cognition Lab\nConducted research on language, semantic memory, and progressive language impairment in dementia. Co-led eye-tracking research, administering tests and analyzing patient data. Gained experience with eye-tracking technology, EEG, and developing support guides for individuals with dementia and traumatic brain injury.\nResearch Assistant, Aphasia Rehabilitation Lab\nStudied the cognitive relationship between verbal short-term memory and word processing disorders. Administered language assessments (Stroop Test, Boston Naming Test) and managed research data. Assisted in database organization for prior studies.\n\n\n\nUltimately, my career goal is to become a neuroscientist in the pharmaceutical or biotechnology industry, conducting research and development on new drugs or treatments for neurological conditions with a focus on drug discovery, clinical trials, and regulatory affairs.\n\n\n\nFeel free to reach out on any of my social media platforms below. Let’s explore the brain together!"
  },
  {
    "objectID": "about.html#welcome-to-my-blog",
    "href": "about.html#welcome-to-my-blog",
    "title": "About Me",
    "section": "",
    "text": "Hello, my name is Nicholas Monogioudis, a recent neuroscience graduate passionate about clinical research, biotech, and AI in neuroscience.\n\n\nThis blog is where I share my insights on neuroscience, research breakthroughs, and industry trends, with a special focus on cognitive neuroscience, neuropharmacology, and neurotechnology.\nI aim to bridge the gap between complex neuroscience concepts and real-world applications, making cutting-edge research more accessible. Whether you’re a student, researcher, or simply someone curious about the brain, you’ll find content here on:\nThe latest discoveries in neuroscience and what they mean for the future\nDeep dives into cognitive processes, brain function, and neural networks\nHow neuroscience is shaping the pharmaceutical and biotech industries\nThe intersection of neuroscience with AI, brain-computer interfaces, and neurotech\nPersonal reflections on my journey in neuroscience and industry insights\n\n\n\nEducation: B.Sc. in Neuroscience from Temple University\nResearch Experience:\nResearch Assistant, Concepts and Cognition Lab\nConducted research on language, semantic memory, and progressive language impairment in dementia. Co-led eye-tracking research, administering tests and analyzing patient data. Gained experience with eye-tracking technology, EEG, and developing support guides for individuals with dementia and traumatic brain injury.\nResearch Assistant, Aphasia Rehabilitation Lab\nStudied the cognitive relationship between verbal short-term memory and word processing disorders. Administered language assessments (Stroop Test, Boston Naming Test) and managed research data. Assisted in database organization for prior studies.\n\n\n\nUltimately, my career goal is to become a neuroscientist in the pharmaceutical or biotechnology industry, conducting research and development on new drugs or treatments for neurological conditions with a focus on drug discovery, clinical trials, and regulatory affairs.\n\n\n\nFeel free to reach out on any of my social media platforms below. Let’s explore the brain together!"
  }
]